The Quigley Corporation To Present At NYSSA Biotech/Specialty Pharma Conference

DOYLESTOWN, Pa., Dec. 6 /PRNewswire-FirstCall/ -- The Quigley Corporation announced today that Guy J. Quigley, Chairman, President and Chief Executive Officer, and other members of senior management of the Company, will be making a presentation at the New York Society of Security Analysts (NYSSA) 10th Annual Biotech/Specialty Pharma Industry investor conference in New York City on Wednesday, December 13, 2006.

The presentation will be web cast live at http://www.QuigleyPharma.com on Wednesday, December 13, 2006 at 11:00AM Eastern Time. The web cast will be archived following the presentation and a replay may be accessed at the same link.

"We are pleased by the opportunity to provide an overview of the Company and its operations to the financial community and our investors," said Guy J. Quigley, Chairman, President and Chief Executive Officer.

About The Quigley Corporation

The Quigley Corporation is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries. Darius International markets health and wellness products through its wholly owned subsidiary, InnerLight Inc. Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD-EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

CONTACT: Media Investor Relations Karen Pineman Carl Hymans G.S. Schwartz & Co. G.S. Schwartz & Co. 212.725.4500 212.725.4500 kpineman@schwartz.comcarlh@schwartz.com

CONTACT: Media: Karen Pineman, kpineman@schwartz.com, or InvestorRelations: Carl Hymans, carlh@schwartz.com, both of G.S. Schwartz & Co.,+1-212-725-4500

Web site: http://www.quigleyco.com/